摘要
目的探讨贝伐珠单抗联合替莫唑胺治疗经放疗、手术、化疗、靶向治疗以及脱水等对症治疗后进展的难治性脑转移瘤的临床疗效。方法选取2014年6月至2020年6月包头市中心医院肿瘤科住院的脑转移瘤复发患者46例,随机分为观察组和对照组,每组各23例,两组患者均给予口服替莫唑胺胶囊化疗,观察组在口服替莫唑胺胶囊化疗的基础上加予贝伐珠单抗。评估两组患者化疗2周期后的疾病控制率以及不良反应发生情况。结果观察组患者的疾病控制率明显高于对照组患者(73.9%>39.1%),提示观察组治疗的近期有效率优于对照组,差异有统计学意义(P<0.05);两组患者的不良反应主要为骨髓抑制、消化道反应、高血压以及蛋白尿等,其中不同程度的高血压和蛋白尿在观察组中的发生率明显高于对照组(P<0.05)。结论贝伐珠单抗联合替莫唑胺后线治疗难治性脑转移瘤近期疗效较好、可耐受。
Objective To investigate the clinical efficacy of bevacizumab combined with temozolomide in the treatment of refractory brain metastases that had progressed after symptomatic treatment including radiotherapy,surgery,chemotherapy,targeted therapy and dehydration.Methods A total of 46 patients with recurrent brain metastatic tumor admitted to the Department of Oncology of Baotou Central Hospital from June 2014 to June 2020 were randomly divided into observation group and control group,with 23 patients in each group.The control group was given oral temozolomide chemotherapy,and the observation group was given bevacizumab in addition to oral temozolomide chemotherapy.The disease control rate and adverse reactions were evaluated after 2 cycles of chemotherapy in the two groups.Results The disease control rate of the observation group was higher than that of the control group(73.9%vs 39.1%),indicating that the short-term effective rate of the observation group was better than that of the control group,and the difference was statistically significant(P<0.05).The main adverse reactions in 2 groups were bone marrow suppression,gastrointestinal reaction,hypertension,proteinuria,etc.The incidence of hypertension and proteinuria in the observation group was significantly higher than that in the control group(P<0.05).Conclusion The short-term efficacy of bevacizumab combined with temozolomide in the treatment of refractory brain metastases is good and the patient was well tolerated.
作者
郝志强
刘波
杨海祥
朱巍
HAO Zhi-qiang;LIU Bo;YANG Hai-xiang;ZHU Wei(Department of Oncology,Baotou Central Hospital·Institute of Cancer Prevention and Treatment,Baotou Medical College,Baotou 014040 China)
出处
《内蒙古医学杂志》
2022年第4期410-412,共3页
Inner Mongolia Medical Journal
关键词
贝伐珠单抗
替莫唑胺
脑转移瘤
近期疗效
bevacizumab
temozolomide
brain metastases
the recent curative effect
